Novo Nordisk Ties $200 Million to Diabetes Care as Liver Data and Eye-Risk Labels Frame Semaglutide's Next Chapter
Published on 11/11/2026 at 20:30 | Editorial boerse-global.de
Novo Nordisk has committed USD 200 million to the World Diabetes Foundation, earmarking the funds for 2027–2036 to back diabetes prevention and treatment in low- and middle-income countries. The pledge lands alongside a pair of disclosures that sketch out both the promise and the regulatory friction surrounding the company's flagship GLP-1 franchise.
On the clinical side, Novo Nordisk presented observational data at the AASLD Liver Meeting on Friday covering Wegovy in adults with MASH. According to the company, treatment with 2.4 mg semaglutide was linked to lower liver enzyme levels, reduced weight and lower blood sugar. Novo Nordisk was explicit that the studies cannot establish causality — these are real-world practice data, not proof that the drug drove the changes observed.
One of the analyses put semaglutide head-to-head with resmetirom. At the six-month mark, semaglutide was associated with an average weight loss of 8.6 kilograms, or roughly 8%, at the 2.4 mg dose. Separate from the observational work, Novo Nordisk reported a post-hoc evaluation of the Phase 3 ESSENCE trial, which showed improvements in liver markers versus placebo. That group covered adults with MASH, liver scarring and a BMI below 27 kg/m² — a patient population examined after the fact rather than pre-specified.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
FDA Wants NAION Language on Labels
Regulators, meanwhile, have moved on the safety front. The US Food and Drug Administration has required manufacturers of GLP-1 drugs to add information on a possible NAION risk, a condition that can trigger sudden vision loss. For Novo Nordisk, the requirement covers Ozempic and Wegovy, with the details slated for the warnings and precautions section of the product labeling. An AP report cited the FDA finding the condition in roughly six of every 100,000 patients who took a GLP-1 medicine for at least a year.
The financial backdrop has shifted too. A little over a week ago the Danish drugmaker raised its full-year 2026 outlook for adjusted sales and adjusted operating profit to a currency-neutral range of -2% to +2%. The prior guidance had pointed to anything from flat performance to a 6% decline.
Third-quarter 2026 numbers underlined the momentum: adjusted sales climbed 4% at constant currencies, while adjusted operating profit jumped 27% on the same basis to DKK 31.7 billion.
Ad
Novo Nordisk Stock: New Analysis - 11 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
